Eduardo Nieto-Ortega
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eduardo Nieto-Ortega has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Navarrete Peón
Universidad Autónoma del Estado de Hidalgo, México
4 shared publications - Alejandro Durán-Méndez
Universidad Autónoma del Estado de Hidalgo
2 shared publications - Diana Ali Macedo-Falcon2 shared publications
Aldo Christiaan Jardínez-Vera
Escuela Superior de Apan, Universidad Autónoma del Estado de Hidalgo, Chimalpa Tlalayote, Mexico
1 shared publicationAlma Delia Aguilar-Arroyo
Laboratorio Santiago Ramón y Cajal, Sociedad Española de Beneficencia, Pachuca, Mexico
1 shared publicationAmérica Viveros-Hernández
Laboratorio Santiago Ramón y Cajal, Sociedad Española de Beneficencia, Pachuca, Mexico
1 shared publication
Latest Publications
- 2 May 2022
- Published by Sociedad Espanola de Beneficencia
- Vol. 3 (2) , 1-15
Calculadora de riesgo de progresión a hospitalización por COVID-19, enfermedad crítica y muerte. Estudio retrospectivo observacional.
COVID-19 pandemics has spread at a fast rate worldwide, producing multiple collapses in the healthcare system worldwide. In such setting, the correct priorization of regular hospital beds and intensive care unit beds is mandatory in order to save more lives and optimize resource usage. Currently, some specific online calculators are available, and prognostic clinical scores like NEWS and SOFA have been repurposed to evaluate potential for disease progression in COVID-19 patients. Nonetheless, the predictive value of these tools has been low in practice. Nowadays, the knowledge about pathological markers is more advanced, and unlike when the aforementioned studies were published, it is now recognized that COVID-19 has at least three different symptomatic stages, each governed by distinctive pathophysiological traits. Thus, we think that a risk calculator that incorporates the aforementioned knowledge may have a strong predictive ability.
- 2 May 2022
- Published by Sociedad Espanola de Beneficencia
- Vol. 3 (2) , 1-15
Calculadora de riesgo de progresión a hospitalización por COVID-19, enfermedad crítica y muerte. Estudio retrospectivo observacional.
COVID-19 pandemics has spread at a fast rate worldwide, producing multiple collapses in the healthcare system worldwide. In such setting, the correct priorization of regular hospital beds and intensive care unit beds is mandatory in order to save more lives and optimize resource usage. Currently, some specific online calculators are available, and prognostic clinical scores like NEWS and SOFA have been repurposed to evaluate potential for disease progression in COVID-19 patients. Nonetheless, the predictive value of these tools has been low in practice. Nowadays, the knowledge about pathological markers is more advanced, and unlike when the aforementioned studies were published, it is now recognized that COVID-19 has at least three different symptomatic stages, each governed by distinctive pathophysiological traits. Thus, we think that a risk calculator that incorporates the aforementioned knowledge may have a strong predictive ability.
- 25 January 2022
- Published by Sociedad Espanola de Beneficencia
- Vol. 3 (1) , 1-8
Evaluation of drug-drug interactions in hospitalized patients at Sociedad Española de Beneficencia
Background: drug-drug interactions are a frequent cause of adverse drug reactions, the use of more than 5 drugs is significantly related to serious interactions. Comorbidities in patients have precipitated the frequency of polypharmacy, which produces an enhanced incidence of morbidity and mortality, hospital stay and costs. Materials and methods: 50 records of hospitalized patients were analyzed in the period from May to July 2019, a search for drug interactions was carried out with the help of Medscape Drug-Interactions Checker and the Drugs Interactions Checker. Results: 68% of the records presented at least one pharmacological interaction, the majority associated with musculoskeletal pathology and abdominal pain syndrome (45 and 29%, respectively). On the other hand, 48% of the interactions were related to the use of non-steroidal anti-inflammatory drugs and the use of opioid pain relievers combined with sedatives or anesthetics. Conclusions: there is a significant incidence in drug interactions, most of them related to poor pain management, however, it is essential to know the pathophysiology of each patient's disease, and to understand that the benefit must be greater than the risk when indicating the best therapy for the patient.
- 25 January 2022
- Published by Sociedad Espanola de Beneficencia
- Vol. 3 (1) , 1-8
Evaluation of drug-drug interactions in hospitalized patients at Sociedad Española de Beneficencia
Background: drug-drug interactions are a frequent cause of adverse drug reactions, the use of more than 5 drugs is significantly related to serious interactions. Comorbidities in patients have precipitated the frequency of polypharmacy, which produces an enhanced incidence of morbidity and mortality, hospital stay and costs. Materials and methods: 50 records of hospitalized patients were analyzed in the period from May to July 2019, a search for drug interactions was carried out with the help of Medscape Drug-Interactions Checker and the Drugs Interactions Checker. Results: 68% of the records presented at least one pharmacological interaction, the majority associated with musculoskeletal pathology and abdominal pain syndrome (45 and 29%, respectively). On the other hand, 48% of the interactions were related to the use of non-steroidal anti-inflammatory drugs and the use of opioid pain relievers combined with sedatives or anesthetics. Conclusions: there is a significant incidence in drug interactions, most of them related to poor pain management, however, it is essential to know the pathophysiology of each patient's disease, and to understand that the benefit must be greater than the risk when indicating the best therapy for the patient.
- Open Access
- 5 January 2022
- Published by Universidad Autonoma del Estado de Hidalgo in Pädi Boletín Científico de Ciencias Básicas e Ingenierías del ICBI
- Vol. 9 (18) , 146-152
Inmunosupresión vs. Inmunorregulación en COVID-19
La COVID-19 tiene un espectro clínico variable, desde una infección asintomática hasta una enfermedad crítica con desenlace mortal. Se han propuesto múltiples terapias, algunas con efectos a nivel de la respuesta inmunológica. En este estudio evaluamos el uso de Tocilizumab, Colchicina y Baricitinib en pacientes hospitalizados con infección por SARS-CoV-2. Se examinaron los expedientes clínicos de 133 pacientes hospitalizados con COVID-19 en 3 hospitales. Inicialmente, ninguno de estos medicamentos mostró ser superior al grupo Control en disminuir la mortalidad. Sin embargo, se realizó un análisis estratificado evidenciando que Tocilizumab puede reducir la mortalidad hasta un 3.7% vs 28.12% (p=0.01). La estancia intrahospitalaria fue mayor en los pacientes que recibieron Baricitinib y Tocilizumab comparados con el Control (14.25±2.06 y 10.58±3.66 respectivamente vs 8.30±2.86). Finalmente, Tocilizumab fue el único fármaco que redujo la probabilidad de un aumento en el requerimiento de oxígeno suplementario (OR 0.3094, 0.95% IC [0.1031-0.9287]). La terapia inmunorreguladora muestra ser útil para el manejo de pacientes con COVID-19.
- 5 January 2022
- Published by Universidad Autonoma del Estado de Hidalgo in Pädi Boletín Científico de Ciencias Básicas e Ingenierías del ICBI
- Vol. 9 (18) , 146-152
Open AccessInmunosupresión vs. Inmunorregulación en COVID-19
La COVID-19 tiene un espectro clínico variable, desde una infección asintomática hasta una enfermedad crítica con desenlace mortal. Se han propuesto múltiples terapias, algunas con efectos a nivel de la respuesta inmunológica. En este estudio evaluamos el uso de Tocilizumab, Colchicina y Baricitinib en pacientes hospitalizados con infección por SARS-CoV-2. Se examinaron los expedientes clínicos de 133 pacientes hospitalizados con COVID-19 en 3 hospitales. Inicialmente, ninguno de estos medicamentos mostró ser superior al grupo Control en disminuir la mortalidad. Sin embargo, se realizó un análisis estratificado evidenciando que Tocilizumab puede reducir la mortalidad hasta un 3.7% vs 28.12% (p=0.01). La estancia intrahospitalaria fue mayor en los pacientes que recibieron Baricitinib y Tocilizumab comparados con el Control (14.25±2.06 y 10.58±3.66 respectivamente vs 8.30±2.86). Finalmente, Tocilizumab fue el único fármaco que redujo la probabilidad de un aumento en el requerimiento de oxígeno suplementario (OR 0.3094, 0.95% IC [0.1031-0.9287]). La terapia inmunorreguladora muestra ser útil para el manejo de pacientes con COVID-19.
- Open Access
- 5 October 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-8
Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study
Life-threatening COVID-19 is associated with strong inflammation, where an IL-6-driven cytokine storm appears to be a cornerstone for enhanced pathology. Nonetheless, the specific inhibition of such pathway has shown mixed outcomes. This could be due to variations in the dose of tocilizumab used, the stage in which the drug is administered or the severity of disease presentation. Thus, we performed a retrospective multicentric study in 140 patients with moderate to critical COVID-19, 79 of which received tocilizumab in variable standard doses (< 400 mg, 400–800 mg or > 800 mg), either at the viral (1–7 days post-symptom onset), early inflammatory (8–15) or late inflammatory (16 or more) stages, and compared it with standard treated patients. Mortality, reduced respiratory support requirements and pathology markers were measured. Tocilizumab significantly reduced the respiratory support requirements (OR 2.71, CI 1.37–4.85 at 95%) and inflammatory markers (OR 4.82, CI 1.4–15.8) of all patients, but mortality was only reduced (4.1% vs 25.7%, p = 0.03) when the drug was administered at the early inflammatory stage and in doses ranging 400–800 mg in severely-ill patients. Despite the apparent inability of Tocilizumab to prevent the progression of COVID-19 into a critical presentation, severely-ill patients may be benefited by its use in the early inflammatory stage and moderate doses.
- 5 October 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-8
Open AccessTocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study
Life-threatening COVID-19 is associated with strong inflammation, where an IL-6-driven cytokine storm appears to be a cornerstone for enhanced pathology. Nonetheless, the specific inhibition of such pathway has shown mixed outcomes. This could be due to variations in the dose of tocilizumab used, the stage in which the drug is administered or the severity of disease presentation. Thus, we performed a retrospective multicentric study in 140 patients with moderate to critical COVID-19, 79 of which received tocilizumab in variable standard doses (< 400 mg, 400–800 mg or > 800 mg), either at the viral (1–7 days post-symptom onset), early inflammatory (8–15) or late inflammatory (16 or more) stages, and compared it with standard treated patients. Mortality, reduced respiratory support requirements and pathology markers were measured. Tocilizumab significantly reduced the respiratory support requirements (OR 2.71, CI 1.37–4.85 at 95%) and inflammatory markers (OR 4.82, CI 1.4–15.8) of all patients, but mortality was only reduced (4.1% vs 25.7%, p = 0.03) when the drug was administered at the early inflammatory stage and in doses ranging 400–800 mg in severely-ill patients. Despite the apparent inability of Tocilizumab to prevent the progression of COVID-19 into a critical presentation, severely-ill patients may be benefited by its use in the early inflammatory stage and moderate doses.